New treatment approach for hard-to-treat multiple myeloma
Novel Targeted Therapy for Refractory Multiple Myeloma
['FUNDING_OTHER'] · ROWAN UNIVERSITY · NIH-11074538
This study is testing a new treatment for multiple myeloma, especially to help African American patients who often face tougher challenges with the disease, by looking at how a special molecule can make current therapies work better against cancer cells that are hard to treat.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | ROWAN UNIVERSITY (nih funded) |
| Locations | 1 site (GLASSBORO, UNITED STATES) |
| Trial ID | NIH-11074538 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a novel therapy for multiple myeloma, a type of cancer affecting plasma cells in the bone marrow. It aims to address the racial disparities in treatment outcomes, particularly for African American patients who experience higher mortality rates. The study investigates the role of specific enzymes, known as aldehyde dehydrogenases (ALDH), that contribute to treatment resistance in cancer stem-like cells. By using a new small molecule inhibitor, KS100, the research seeks to enhance the effectiveness of existing treatments and improve patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are African American patients diagnosed with refractory multiple myeloma who have not responded well to standard treatments.
Not a fit: Patients with early-stage multiple myeloma or those who have not yet undergone treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for multiple myeloma, particularly benefiting African American patients who currently face worse outcomes.
How similar studies have performed: Other research has shown promise in targeting cancer stem cells and overcoming treatment resistance, suggesting that this approach could be effective.
Where this research is happening
GLASSBORO, UNITED STATES
- ROWAN UNIVERSITY — GLASSBORO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: PANDEY, MANOJ KUMAR — ROWAN UNIVERSITY
- Study coordinator: PANDEY, MANOJ KUMAR
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.